

Paris, 4 October 2021

**Re: Clinical Trial Posting results**

**Product:** ALXN1830

**Protocol number** ALXN1830-WAI-201

**EudraCT number** 2019-004055-37

**Protocol title** A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia (WAIHA)

**Sponsor:** Alexion Pharmaceuticals Incorporated, USA

**EU legal representative:** Alexion Europe SAS, France

Reference is made to ALXN1830-WAI-201 study for ALXN1830, a humanized, affinity-matured IgG4-kappa monoclonal antibody targeted against the neonatal Fc receptor (FcRn).

The global end of trial for Study ALXN1830-WAI-201 occurred on 28 May 2020 due to the ongoing global COVID-19 pandemic.

No patient has been enrolled in this study globally. As a result, no clinical study results is available.

I trust that you will find the documentation satisfactory. Please do not hesitate to contact me should you require any further information.

Yours faithfully,

Alexion Europe SAS

Tel : +33787148158

e-mail : ClinicalTrials.EU@alexion.com